- Home
- BSBK vs CTOR Comparison
BSBK vs CTOR Comparison
Compare BSBK & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSBK
- CTOR
- Stock Information
- Founded
- BSBK 1893
- CTOR 2021
- Country
- BSBK United States
- CTOR United States
- Employees
- BSBK N/A
- CTOR N/A
- Industry
- BSBK Banks
- CTOR
- Sector
- BSBK Finance
- CTOR
- Exchange
- BSBK Nasdaq
- CTOR NYSE
- Market Cap
- BSBK 105.3M
- CTOR 89.9M
- IPO Year
- BSBK N/A
- CTOR N/A
- Fundamental
- Price
- BSBK $7.94
- CTOR $1.17
- Analyst Decision
- BSBK
- CTOR Strong Buy
- Analyst Count
- BSBK 0
- CTOR 2
- Target Price
- BSBK N/A
- CTOR $4.50
- AVG Volume (30 Days)
- BSBK 5.4K
- CTOR 61.5K
- Earning Date
- BSBK 02-14-2025
- CTOR 02-14-2025
- Dividend Yield
- BSBK N/A
- CTOR N/A
- EPS Growth
- BSBK N/A
- CTOR N/A
- EPS
- BSBK N/A
- CTOR N/A
- Revenue
- BSBK $12,047,614.00
- CTOR N/A
- Revenue This Year
- BSBK N/A
- CTOR N/A
- Revenue Next Year
- BSBK N/A
- CTOR N/A
- P/E Ratio
- BSBK N/A
- CTOR N/A
- Revenue Growth
- BSBK N/A
- CTOR N/A
- 52 Week Low
- BSBK $6.40
- CTOR $0.85
- 52 Week High
- BSBK $8.66
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- BSBK 51.72
- CTOR N/A
- Support Level
- BSBK $7.70
- CTOR N/A
- Resistance Level
- BSBK $8.16
- CTOR N/A
- Average True Range (ATR)
- BSBK 0.20
- CTOR 0.00
- MACD
- BSBK 0.01
- CTOR 0.00
- Stochastic Oscillator
- BSBK 60.46
- CTOR 0.00
About BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from, customers in New Jersey.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.